Rucaparib (AG-014699,PF-01367338) phosphate

目录号:S1098

Rucaparib (AG-014699,PF-01367338) phosphate Chemical Structure

Molecular Weight(MW): 421.36

Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂,无细胞试验中作用于PARP1的Ki为1.4 nM,对其余8个PARP位点也有结合亲和力。Phase 3。

规格 价格 库存 购买数量  
RMB 1091.92 现货
RMB 980.68 现货
RMB 1730.04 现货
RMB 5483.69 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • For anchorage dependent clonogenic assays, HER2+ breast cancer BT474 cells were seeded at low density in 6-well plates and allowed to adhere overnight. The next day, olaparib and rucaparib were added at the indicated concentrations. Media and drugs were replenished every three days. After 10-15 days, depending on cell proliferation rate, cells were fixed and stained with crystal violet. Images and graphs indicate the results compared to control condition. Data are mean ± S.D. n.s.: non-significant, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

    Eur J Cancer 2014 50(15), 2725-34. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    Total cell extracts of BT-474 cells treated with increasing concentrations of olaparib or rucaparib were subjected to western blot analysis for PARP-1 and poly ADP-ribose (PAR) expression. β-tubulin was used as loading control. Representative images from two separate experiments are shown.

    Eur J Cancer 2014 50(15), 2725-34. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

  • purified PARP-1 and His-XPA were incubated alone ( lane 7 ), with activated PARP-1 (addition of activated DNA and NAD+, lane 8 ), or in the presence of the PARP inhibitor AG-014699 (lane 9 ). Following the various treatments, His-XPA was pulled down ( IP ) from each sample using cobalt-conjugated magnetic beads.

    J Biol Chem 2012 287, 39824-33. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    Three sensitive and three resistant cell lines were treated for 24 h with 0.02% DMSO (negative control) or 10 uM rucaparib. Serving as positive control were cells fixed 30 min after exposure to 2 Gy IR. Image acquisition was performed with a confocal microscope (Leica TCS SP2) using the 100X objective and a 2X optical zoom and oil immersion. Red: γH2AX foci. Green: RAD51 foci. *P < 0.05 **P < 0.01 ***P < 0.001. Fluorescence microscopy images of DAPI-stained rucaparib-sensitive (HN4) and rucaparib-resistant (SAS) HNC cell lines treated with DMSO, 2 Gy or 10 uM rucaparib for 24 h.

    Oral Oncol 2014 50(9), 825-31. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

  • Antitumor effects of transfecting of INPP4B gene combined with PARP inhibitor treatment on PC3 cells. (A) The change of cell number and shape under the microscope. (B) The viability of PC3 cells measured using CCK-8. (C) The cell cycle phase distribution of PC3 detected by flow cytometry. (D) Apoptosis of PC3 cells detected using annexin V-FITC/PI staining. (Asterisks denote statistical significance between Lenti-INPP4B+PARP inhibitor and Lenti-INPP4B and PARP inhibitor treatment, *P<0.05).

    Urol Oncol 2014 32(5), 720-6. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AG-014699 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AG-014699 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    Dr. David Schrmann from University of Base. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂,无细胞试验中作用于PARP1的Ki为1.4 nM,对其余8个PARP位点也有结合亲和力。Phase 3。
特性 AG-014699是第一个用于人类癌症疗法的PARP 抑制剂。
靶点
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外研究

AG-014699有效抑制纯化的全长人类PARP-1,作用于LoVo和SW620细胞显示出强PARP抑制效果。AG-014699是AG14447的磷酸盐形式,且是第一个和temozolomide联用用于临床实验的PARP抑制剂。[1] AG-014699的辐射增敏性是由于下游NF-κB激活的抑制,及SSB修复抑制。AG-014699可以作用于DNA损伤激活的NF-κB,且克服传统NF-κB抑制剂的毒性,不会损害其他重要的炎症反应。[2]1μM AG-014699作用于D283Med细胞时抑制PARP-1活性达97.1%。[3]在NB-1691, SH-SY-5Y, 和SKNBE(2c)细胞中AG-014699明显增强Topotecan和Temozolomide的细胞毒性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 M{\MdWZ2dmO2aX;uJGF{e2G7 MVuwMlEwOS93MECvNVAxOCCwTR?= NHHGNYdqdmirYnn0d{BRSVKSIHHjeIl3cXS7IHH0JJN1[XK2aX7nJINwdmOncn70doF1cW:wIH;mJFUxOCCwTR?= Mo\QNlUyOjh2NUW=
BT474 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm5UW1CPTByIH7N MkPWNVDjiJNzNdMg[C=> MXPy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC|aXfubYZq[2GwdHz5 MlTaNlUyOjh2NUW=
SKBR3 NEOzTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;6TFUxOCCwTR?= NGLlblUyOOLCk{G1xsBl NH3qXGhz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6 MVqyOVEzQDR3NR?=
AU565 M1fac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvjNFI2ODBibl2= NF3XeYcyOOLCk{G1xsBl NXrCZnA3emWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? NW\6XXhHOjVzMki0OVU>
EFM192A NH7VZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\pclM2ODBibl2= NGPOS4syOOLCk{G1xsBl MWry[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC|aXfubYZq[2GwdHz5 MXGyOVEzQDR3NR?=
MDA-MB-231 M{XiSWZ2dmO2aX;uJGF{e2G7 M4H2WlExNzJyL{SwJO69VQ>? M{LocVI1KGh? NF[3U4dqdmO{ZXHz[ZMheC2DS2SgcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MX:yOFQzODF3Mh?=
MDA-MB-231 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVjnTHBtOC5zLUSwJO69VQ>? NXPNSHluOjRiaB?= NGm4NYFKSzVy4pEJQgKBkTF5Lke3xsDPxE1? MWmyOFQzODF3Mh?=
MDA-MB-231 NIThToFCeG:ydH;zbZMhSXO|YYm= MUOxNE8zOC92MDFOwG0> MmfUNlQhcA>? MWPpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NU\QWIE2OjR2MkCxOVI>
MDA-MB-231 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrabJBnOTBxMkCvOFAh|ryP M{S0PFI1KGh? MXnicI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvckBqdiCJMj;NJJBp[XOn NWnaXY9WOjR2MkCxOVI>
H460 NVTze206T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLQdZU1ODBibl2= NWLnPZVROjUEoHi= NWLFT3o2cW6lcnXhd4V{KGOnbHz1cIFzKHKjZHnvd4Vve2m2aY\peJk> M1r1[lI1PDFzNkGx
A549  M3TpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu0NFAhdk1? NIXNWY8zPMLiaB?= MmnNbY5kemWjc3XzJINmdGy3bHHyJJJi\Gmxc3Xud4l1cX[rdIm= NXvTOpVsOjR2MUG2NVE>
DT40 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\MdItKSzVyPUKxJI5O MYGyOFM2PjhzMx?=
DU145 NVTTRWU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f4bmlEPTB;MUigcm0> MVGyOFM2PjhzMx?=
COLO704 NETuOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvUdJg1UUN3ME2yMlUzKMLzIECuOlch|ryP M2LxOVI{PzJ7NECy
OVMANAb NFzp[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnER|BIUUN3ME2yMlU5KMLzIECuN|gh|ryP M2DDTlI{PzJ7NECy
OV177 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG1TWM2OD1{Lke4JOKyKDBwN{Gg{txO Ml;SNlM4Ojl2MEK=
OAW28 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTNwNkGgxtEhOC5{ODFOwG0> M17WTFI{PzJ7NECy
OVSAHO NV\RXFdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;RTWM2OD1|Lk[0JOKyKDBwM{Og{txO M170UlI{PzJ7NECy
OVKATE M3vVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzMTWM2OD1|Lk[0JOKyKDFwN{mg{txO MUmyN|czQTRyMh?=
OVCAR3 M{Ltemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnNW2xKSzVyPUOuO|QhyrFiMD60NEDPxE1? NWXHd2l7OjN5Mkm0NFI>
PEO14 M{\EOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7KVGNOUUN3ME2zMlg1KMLzIECuO|Yh|ryP M{PYNVI{PzJ7NECy
A2780 NILOT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTNwOUSgxtEhOC5{NTFOwG0> NH7UWHgzOzd{OUSwNi=>
OVTOKO Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS0OmRKSzVyPUSuNVQhyrFiMT61N{DPxE1? M3\ad|I{PzJ7NECy
KURAMOCHIb NEGyXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK5b3ZKSzVyPUSuN|QhyrFiMD6yPUDPxE1? MX6yN|czQTRyMh?=
TOV21G Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCzTWM2OD13LkC3JOKyKDFwM{Cg{txO NHK1SW4zOzd{OUSwNi=>
OVISE NGXN[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzyeolwUUN3ME21MlY5KMLzIECuNlMh|ryP MV:yN|czQTRyMh?=
KK M1vTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrwOIVKSzVyPU[uNVUhyrFiMT60NkDPxE1? Mke5NlM4Ojl2MEK=
RMUGS NY\4VnV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTdwMEOgxtEhOS56MzFOwG0> MV6yN|czQTRyMh?=
PEO6 MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHuboN3UUN3ME23MlA3KMLzIECuO|Qh|ryP MkPiNlM4Ojl2MEK=
OVCA429 M4DXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe2fZhKSzVyPUiuNlkhyrFiMT62OEDPxE1? NIm0S28zOzd{OUSwNi=>
OV167 NUjZelVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRThwM{OgxtEhOS5zODFOwG0> NF\Nc2IzOzd{OUSwNi=>
RMG1 NHTzb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTlwM{KgxtEhOi5|NjFOwG0> M3;ZOlI{PzJ7NECy
OVCAR5 M3zPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LZOGlEPTB;OT61NEDDuSB{LkW5JO69VQ>? M3mydVI{PzJ7NECy
EFO21 M1Ox[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfOXZVKSzVyPUmuPVIhyrFiMT64O{DPxE1? NXn3NYJGOjN5Mkm0NFI>
ES2 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHnTWM2OD1zMD6xNkDDuSBzLkKzJO69VQ>? M1XvXFI{PzJ7NECy
Tyk-nu MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\oZWlEPTB;MUCuNlAhyrFiMT6xNkDPxE1? NIDnOpgzOzd{OUSwNi=>
CAOV3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOzUWdWUUN3ME2xNE4{PyEEsTCwMlg4KM7:TR?= NX\GeVJxOjN5Mkm0NFI>
OV207 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvnTWM2OD1zMj6yO{DDuSByLkOyJO69VQ>? MVmyN|czQTRyMh?=
HEY MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3IV2pKSzVyPUGzMlAyKMLzIECuO|Uh|ryP M13DbFI{PzJ7NECy
DOV13 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmyTWM2OD5zNTFOwG0> M{jLWVI{PzJ7NECy
EFO27 NVy5[29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7I[XpKSzVyPkG1JO69VQ>? MXuyN|czQTRyMh?=
HEY C2 NWj5[pQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzzOHFKSzVyPkG1JO69VQ>? MXeyN|czQTRyMh?=
KOC-7cc M4n4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRjF3IN88US=> M376WlI{PzJ7NECy
MCASb MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRjF3IN88US=> NWG5NnRWOjN5Mkm0NFI>
OAW42 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zOUGlEPTB-MUWg{txO M2nhOFI{PzJ7NECy
OV2008 NWjBR21qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRjF3IN88US=> M2foPVI{PzJ7NECy
OV90 NXvzTVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3DSmRkUUN3ME6xOUDPxE1? MVOyN|czQTRyMh?=
OVCA420b Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;FbotKSzVyPkG1JO69VQ>? M2rPdlI{PzJ7NECy
OVCA432 M{\6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XuSmlEPTB-MUWg{txO NV;tOpV4OjN5Mkm0NFI>
PEA2 NETUWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHkdHBKSzVyPkG1JO69VQ>? M2PnNFI{PzJ7NECy
SKOV3 NXrkbIxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjhTWM2OD5zNTFOwG0> NELpTm0zOzd{OUSwNi=>
TOV112D M4\n[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fh[FAuOyEQvF2= NV;2SFViUUN3ME6xOUDPxE1? NF32[IEzOzd{OUSwNi=>
C4-2 NVXjUlZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMVMh|ryP M1rifFE1KGR? MUTEUXNQ NEeyXIFl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 NYe3c4JTOjN3NkWyOFQ>
PC3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSwMVMh|ryP NUXJZm5nOTRiZB?= NEXRbXJFVVOR NXL4[|l4\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= NWDiRpBGOjN3NkWyOFQ>
DU145 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofpNE0{KM7:TR?= NITpbJAyPCCm NEnzNnpFVVOR NHLDW29l\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MmjlNlM2PjV{NES=
VCaP  MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nXV|AuOyEQvF2= MXyxOEBl MnPjSG1UVw>? M1nqNoRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? NFPu[XczOzV4NUK0OC=>
LNCaP  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof0NE0{KM7:TR?= MlLkNVQh\A>? M2HSR2ROW09? M2S3ZYRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? NXPYdWZVOjN3NkWyOFQ>
MDA-MB-468 NXzHW2lGS2WubDDWbYFjcWyrdImgRZN{[Xl? M{DWVGlEPTB;OT63JO69VQ>? M3GyTFIzPjd6MU[x
MDA-MB-231 NXjqT2kxS2WubDDWbYFjcWyrdImgRZN{[Xl? M4H1OGlEPTB;MUOg{txO MXyyNlY4QDF4MR?=
Cal-51 NF7oT3VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVvQPVBUUUN3ME24MlYh|ryP NHntVmQzOjZ5OEG2NS=>

... Click to View More Cell Line Experimental Data

体内研究 AG-014699无毒,明显增强D384Med移植瘤DNA修复功能蛋白中temozolomide诱导的TGD。药物动力学研究显示在脑组织中也检测到AG-014699,说明AG-014699用于治疗颅内恶性肿瘤具有潜在可能。[3]活体模型(NB1691和SHSY5Y移植瘤)研究显示AG-014699增强temozolomide的抗癌活性,产生彻底且持久的肿瘤衰退现象。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[3]
+ 展开

激酶实验:

不同浓度(0到1μ)AG-014699作用于5×103D283Med 细胞,与只用DMSO处理5×103D283Med细胞相比,来测定PARP活性抑制率。参考GCLP验证试验的PAR标准曲线,在和NAD+及寡核苷酸(底物和激活剂)温育的6分钟期间,使用10H PAR抗体,通过PAR形成量的免疫检测,在细胞样本中测量最大程度刺激的PARP活性。
细胞实验: [3]
+ 展开
  • Cell lines: D425Med, D283Med和D384Med细胞
  • Concentrations: 0.4 μM
  • Incubation Time: 3或5天
  • Method: 髓母细胞瘤细胞系包含D425Med, D283Med,和D384Med细胞,分别按1×103, 3×103,和3×103密度接种在96孔板上。接种24小时(D384Med细胞)或48小时(D283Med和D425Med细胞)后,细胞用不同浓度temozolomide处理。培养3天(D425Med和D384Med细胞)或5天(D283Med细胞)后,通过XTT细胞增殖检测试剂盒检测细胞活力。用DMSO处理的对照组和0.4μ AG-014699处理的实验组的百分比表示细胞生长。计算temozolomide单独使用或者和AG-014699联用时的GI50值。Temozolomide单独使用时的GI50值和与AG-014699联用时的GI50值之比就是趋化因子50(PF50)值。
    (Only for Reference)
动物实验:[3]
+ 展开
  • Animal Models: 携带D283Med移植瘤的CD-1裸鼠
  • Formulation: 盐水溶液
  • Dosages: 1 mg/kg
  • Administration: 腹腔注射,每天1次或4次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次加入纯溶剂:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.36
化学式

C19H18FN3O.H3PO4

CAS号 459868-92-9
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02975934 Recruiting Metastatic Castration Resistant Prostate Cancer Clovis Oncology, Inc.|Foundation Medicine January 2017 Phase 3
NCT02986100 Recruiting Solid Tumor Clovis Oncology, Inc. November 2016 Phase 1
NCT02952534 Recruiting Metastatic Castration Resistant Prostate Cancer Clovis Oncology, Inc.|Foundation Medicine November 2016 Phase 2
NCT02855944 Recruiting Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer Clovis Oncology, Inc.|Foundation Medicine September 2016 Phase 3
NCT02740712 Recruiting Neoplasms Clovis Oncology, Inc. March 2016 Phase 1
NCT02505048 Recruiting Metastatic Breast Cancer UNICANCER|Clovis Oncology, Inc.|Fondation ARC March 2016 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Related Antibodies

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate供应商 | 采购Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate价格 | Rucaparib (AG-014699,PF-01367338) phosphate生产 | 订购Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID